Vischer with Virometix on $ 15 m financing round
Vischer advised Virometix, a clinical-stage biotechnology company developing fully synthetic vaccines, throughout completion of a $15m financing round from existing shareholders.
The company will direct all proceeds from the round to supporting clinical and development activities for V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumo-coccal disease caused by Streptococcus pneumoniae (Spn) infections.
The Vischer team
The Vischer team working on the matter included Matthias Staehelin (pictured), Pauline Pfirter, Natacha Tang and Francesco Catale (all corporate/M&A), as well as Nadia Tarolli (tax).
